<DOC>
	<DOCNO>NCT00557310</DOCNO>
	<brief_summary>The purpose study use image technology demonstrate effect teriparatide bone structure follow 18 24 month therapy postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>A Study Using Imaging Technology Measure Changes Bone Structure After Treatment With Teriparatide</brief_title>
	<detailed_description>As teriparatide approve 24 month treatment US , patient give option continue 6-month extension phase upon completion 18 month teriparatide treatment . This extension allow collection additional bone quality data . In Canada , use teriparatide currently approve 18 month . Patients Canada may give opportunity participate 6-month extension phase , contingent upon Health Canada approval use teriparatide treatment 24 month .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>postmenopausal ( `` change life '' ) woman osteoporosis age 4585 low bone mass determine bone density test least one prior atraumatic vertebral nonvertebral fracture ( Tscore 2.0 low lumbar spine , total hip , femoral neck ) , prior fracture ( Tscore 3.0 low site ) could take 5 year total certain oral osteoporosis medication alendronate , risedronate , ibandronate condition would affect bone region wrist previous fracture either wrist might affect result study metal implant hip replacement either hip might affect result study increase risk osteosarcoma ; include Paget 's disease bone , previous bone tumor , xray treatment skeleton currently active suspect disease affect bone , osteoporosis abnormal level calcium , parathyroid hormone blood , laboratory value</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>osteoporosis , teriparatide , postmenopausal , MRI , finite element analysis</keyword>
</DOC>